77 results
8-K
EX-1.1
HUMA
Humacyte Inc
4 Mar 24
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
6:53am
such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof … is currently the subject or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury
424B5
HUMA
Humacyte Inc
1 Mar 24
Prospectus supplement for primary offering
4:05pm
by contacting our Investor Relations department at Investor Relations, Humacyte, Inc., 2525 East North Carolina Highway 54, Durham, North Carolina 27713.
S … charge to you, upon written request by contacting our Investor Relations department at Investor Relations, Humacyte, Inc., 2525 East North Carolina
424B5
HUMA
Humacyte Inc
29 Feb 24
Prospectus supplement for primary offering
4:11pm
request by contacting our Investor Relations department at Investor Relations, Humacyte, Inc., 2525 East North Carolina Highway 54, Durham, North … are available without charge to you, upon written request by contacting our Investor Relations department at Investor Relations, Humacyte, Inc., 2525 East
424B3
czkoaedrd p9inaf
22 Jun 23
Prospectus supplement
6:50am
8-K
EX-99.1
wp7hstd9
10 Nov 22
Humacyte Third Quarter 2022 Financial Results and Business Update
7:04am
424B3
skds4jtu9 67skqq6
9 Sep 22
Prospectus supplement
4:43pm
424B3
tgxsg5 n4d09
9 Sep 22
Prospectus supplement
4:41pm
S-3
vlya96
1 Sep 22
Shelf registration
4:09pm